WASHINGTON Political leaders paused Sunday to mourn the loss of Arlen Specter, the long-serving former Pennsylvania senator whosefriends and foes across the political spectrumpraised the passionate, if combative, lawmaker who crossed political lines in a way that seems unimaginable in today's partisan era.
"Arlen Specter was always a fighter," President Obama said in a statement."From his days stamping out corruption as a prosecutor in Philadelphia to his three decades of service in the Senate, Arlen was fiercely independent never putting party or ideology ahead of the people he was chosen to serve."
"He brought that same toughness and determination to his personal struggles, using his own story to inspire others," the president said, adding that his efforts to advance stem-cell research funding, veterans health and other issues "will continue to change lives for years to come."Specter died Sunday at 82 afterbattling twice battling cancer, including non-Hodgkin's lymphoma, and other serious illnesses.
Photos: Arlen Specter through the years
His 30-year career in the Senate made him a lion of an earlier and sometimes unrecognizable era in Washington having started his career as a Democrat before becoming a Republican, only to switch once again in his final unsuccessful reelection campaign in 2010.
Specter's most notable work came on the Judiciary Committee, where he played key roles in confirmation of presidential appointees to the Supreme Court, particularly his grilling of Anita Hill during the Clarence Thomas hearings. Even before his late-career switch back to the Democratic Party he provided crucial support for Obama's policies.
"Sen. Specter was a man of moderation; he was always passionate but always easy to work with," said Senate Majority Leader Harry Reid (D-Nev.). "America is better today because of Arlen Specter.
Republican Sen. Orrin Hatch of Utah, who had workedopposite Specter as the top Republican on the Judiciary Committee, recalled his "longtime friend and colleague" as "a spirited man" who represented his state's values with "great integrity and conviction." Chad Griffin, the chairman of the Human Rights Campaign, the nation's largest gay rights advocacy group, noted Specter's critical vote to repealthe "Don't Ask, Don't Tell" law barring gaypersonnel from serving opening inthe military. Obama signed the bill into law in 2010.
"While we disagreed with his support for some conservative judicial nominees, which will leave a lasting negative impact on our community, he was willing to work across party lines to get things done," Griffin said in a statement, noting Specter's support for funding for stem cell research "at a time when it was difficult for a Republican senator to speak out."
Photos: Notable deaths of 2012
Read the original here:
Arlen Specter praised as fighter from a more moderate era
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020